Sleep Disruption and Alzheimer's Disease — mechanism and intervention

Rationale

Rationale

Sleep disturbances are among the earliest biomarkers of AD, often preceding cognitive decline by years. This experiment addresses AD Knowledge Gap #10 (28 points, High): "How does sleep disruption contribute to AD pathogenesis?" [@ju2013]

The bidirectional relationship between sleep disruption and AD pathology represents a critical therapeutic target. Epidemiological studies consistently demonstrate that individuals with chronic sleep disorders have 1.5-2x increased risk of developing AD, while patients with established AD exhibit progressive sleep-wake cycle disruption that correlates with disease severity. Understanding this relationship offers opportunities for both early intervention and disease modification. [@cummings2021]

Background

Sleep Architecture and Neurodegeneration

The human sleep-wake cycle consists of distinct stages with differential effects on brain physiology. Non-rapid eye movement (NREM) sleep, particularly slow-wave sleep (SWS) stages N3, is characterized by high-amplitude, low-frequency cortical oscillations that drive the glymphatic system—the brain's waste clearance pathway. During SWS, astrocyte-mediated perivascular cerebrospinal fluid (CSF) flow increases dramatically, facilitating the removal of metabolic byproducts including amyloid-beta (Aβ) and tau proteins. [@nedergaard2013]

Rapid eye movement (REM) sleep, associated with dreaming and memory consolidation, involves distinct neurophysiological processes. REM sleep behavior disorder (RBD), characterized by loss of muscle atonia during REM sleep, has emerged as a powerful prodromal marker for synucleinopathies including AD with Lewy bodies. The presence of RBD in AD patients correlates with more aggressive pathology and faster disease progression. [@braak2006]

The Glymphatic System

The glymphatic system, first characterized by Iliff and colleagues in 2013, represents a macroscopic waste clearance pathway operating within the brain's perivascular spaces. This system relies on astroglial aquaporin-4 (AQP4) water channels localized to astrocytic end-feet ensheathing cerebral blood vessels. During sleep, the brain's extracellular space expands by over 60%, facilitating bulk flow of interstitial fluid (ISF) and enabling efficient clearance of metabolic waste products. [@xie2013]

The glymphatic system demonstrates circadian periodicity, with maximal clearance efficiency during the natural sleep period. Animal studies demonstrate that sleep deprivation reduces glymphatic flow by over 60%, directly contributing to accumulation of Aβ and tau in brain tissue. Human neuroimaging studies using dynamic contrast-enhanced MRI confirm similar glymphatic dynamics in humans, with one night of sleep deprivation sufficient to increase cortical Aβ burden in healthy adults. [@shokri2018]

Tau Propagation and Sleep

Beyond Aβ accumulation, sleep disruption accelerates tau protein pathology—the second hallmark of AD. Tau is released from neurons into the ISF in an activity-dependent manner, with neuronal firing during wakefulness promoting tau secretion. Sleep reduces neuronal activity and consequently decreases tau release. However, sleep deprivation not only increases tau release but also impairs glymphatic clearance, creating a double hit that promotes both increased burden and reduced removal. [@holth2019]

The concept of "tau spreading" through neural circuits follows a predictable pattern that parallels sleep-wake cycles. Neuronal activity in connected circuits promotes trans-synaptic tau transfer, enabling templated aggregation in recipient neurons. Sleep disruption accelerates this process by increasing neuronal activity while simultaneously reducing clearance. This mechanism may explain the characteristic pattern of tau propagation in AD, beginning in the locus coeruleus and entorhinal cortex before spreading to connected cortical regions. [@liu2020]

Circadian Dysregulation in AD

The circadian system, comprising the suprachiasmatic nucleus (SCN) and peripheral oscillators in virtually every organ system, coordinates sleep-wake cycles with metabolic and cellular processes. In AD, circadian disruption manifests years before clinical diagnosis and progresses with disease severity. This dysfunction involves both central SCN pathology and peripheral clock gene dysregulation in brain cells. [@musiek2018]

Core circadian clock genes (BMAL1, CLOCK, PER, CRY) regulate not only sleep but also cellular metabolism, oxidative stress responses, and protein homeostasis—all processes central to neurodegeneration. Clock gene polymorphisms associate with increased AD risk, while animal models demonstrate that circadian disruption accelerates AD pathology through multiple mechanisms including impaired autophagy, increased oxidative stress, and altered APP processing. [@song2015]

Neuroinflammation and Sleep

Sleep disruption induces robust neuroinflammatory responses through multiple pathways. Microglia, the brain's resident immune cells, exhibit altered morphology and inflammatory cytokine production following sleep deprivation. Pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α increase with sleep loss, and these molecules themselves can fragment sleep, creating a vicious cycle between neuroinflammation and sleep disruption. [@morawska2015]

Neuroinflammation impairs synaptic function and promotes tau pathology through several mechanisms. Activated microglia release exosomes containing inflammatory mediators that alter neuronal protein homeostasis. Additionally, inflammatory cytokines can activate kinases that hyperphosphorylate tau, promoting its aggregation and spread. The sleep-disruption→neuroinflammation→tau pathology cascade represents a key therapeutic target. [@parhizkar2019]

Hypothesis

Sleep disruption contributes to AD through multiple mechanisms: (1) impaired glymphatic clearance of amyloid and tau during slow-wave sleep, (2) circadian disruption of amyloid production/clearance rhythm, (3) hypothalamic-pituitary-adrenal axis dysregulation increasing cortisol, and (4) microglial activation from sleep loss → neuroinflammation. [@nedergaard2020]

We hypothesize that:

Validation Protocol

Phase 1: Longitudinal Sleep-Biomarker Study (Months 1-18)

Cohort: 1,500 participants (500 cognitively normal, 500 MCI, 500 AD) from ADNI, Knight ADRC

Primary Endpoints:

• Change in plasma p-tau217 and p-tau181 over 24 months
• Change in amyloid PET (Centiloid) over 24 months
• Change in sleep architecture (polysomnography) over 24 months

• Polysomnography (PSG) at baseline, 12, 24 months
• Wearable actigraphy (continuous, 14-day periods at each timepoint)
• Plasma p-tau217, p-tau181, NfL, Aβ42/40 at each visit
• CSF biomarkers (subset, n=300): Aβ42/40, t-tau, p-tau181, α-synuclein seeding
• MRI: hippocampal volume, white matter hyperintensities, glymphatic flow (DTI-ALPS)

Phase 2: Mechanism Validation in Preclinical Models (Months 6-24)

Models:

Endpoints:

• Aβ plaque load (Thioflavin S, 6E10 immunohistochemistry)
• Tau phosphorylation (AT8, AT180, PHF-1) and aggregation (MC1 antibody)
• Neuroinflammation (Iba1+ microglial density/morphology, GFAP+ astrocyte coverage)
• Behavior: Morris water maze, Y-maze, novel object recognition

• AQP4 polarization in astrocytic end-feet
• ISF/CSF tracer clearance rates
• Neuronal activity (c-Fos, Arc expression)
• Circadian clock gene expression (qPCR, bioluminescence)

Phase 3: Sleep Intervention Trial (Months 12-30)

Design: Randomized, controlled, multi-arm, assessor-blind

Arms:

Sample: n=400 early AD/MCI patients (MMSE 20-28), age 60-85, with confirmed sleep complaints (PSQI > 5)

Endpoints:

• Primary: Change in plasma p-tau217 at 12 months
• Secondary: Change in ADAS-Cog13, CDR-SB, hippocampal volume, actigraphy-measured sleep efficiency
• Exploratory: CSF biomarkers (subset, n=100), amyloid PET (subset, n=50)

Safety monitoring: Monthly adverse event assessment, fall tracking, cognitive safety monitoring

Phase 4: Glymphatic Enhancement (Months 24-36)

Following successful Phase 3, test enhanced clearance strategies:

Approaches:

Deliverable: Protocol for sleep-based disease modification suitable for clinical implementation

Model Systems

Expected Outcomes

• Primary: Quantify contribution of sleep disruption to amyloid/tau accumulation rate (effect size ~0.4-0.6 SD increase in biomarkers per standard deviation increase in sleep fragmentation)
• Secondary: Identify optimal sleep intervention for AD patients (CBT-I vs pharmacological)
• Tertiary: Glymphatic enhancement protocol ready for clinical testing

Feasibility Assessment

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Technical | 9/10 | PSG and actigraphy standard; preclinical models established; DTI-ALPS validated |
| Timeline | 7/10 | 36 months; cohort enrollment may take 12-18 months |
| Cost | 5/10 | Estimated $5-7M; requires sleep lab infrastructure and multi-site coordination |
| Interpretability | 8/10 | Strong clinical relevance; mechanisms well-theorized; biomarkers validated |

Risk Mitigation

Enrollment: Partner with sleep medicine clinics and memory centers; use digital recruitment platforms

Adherence: Smartphone-based sleep tracking; weekly check-ins; incentive structure

Dropout: Intention-to-treat analysis; multiple imputation for missing data; conservative sensitivity analyses

Cost Estimate

| Phase | Cost | Duration |
|-------|------|----------|
| Phase 1 (Longitudinal) | $1.5M | 18 months |
| Phase 2 (Preclinical) | $1.2M | 18 months |
| Phase 3 (Trial) | $2.5M | 18 months |
| Phase 4 (Enhancement) | $1.0M | 12 months |
| Total | $6.2M | 48 months |

References

See Also

• [AD Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked)
• [Glymphatic-Circadian Axis in PD](/experiments/glymphatic-circadian-axis-parkinsons)
• [Sleep Disorders in Neurodegeneration](/diseases/sleep-disorders-neurodegeneration)
• [Tau Propagation in AD](/mechanisms/tau-propagation-psp)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)